menu
    • menu
    [{"orgOrder":0,"company":"GE Healthcare","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"Ioflupane","moa":"Dopamine transporter (DAT)","graph1":"Neurology","graph2":"Phase III","graph3":"GE Healthcare","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GE Healthcare \/ PPD","highestDevelopmentStatusID":"10","companyTruncated":"GE Healthcare \/ PPD"},{"orgOrder":0,"company":"GE Healthcare","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"Ioflupane","moa":"Dopamine transporter (DAT)","graph1":"Undisclosed","graph2":"Phase I","graph3":"GE Healthcare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"GE Healthcare \/ PPD","highestDevelopmentStatusID":"6","companyTruncated":"GE Healthcare \/ PPD"}]

    Find Clinical Drug Pipeline Developments & Deals for Ioflupane

    Menu

    Ioflupane

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            GE Healthcare

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            GE Healthcare

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ioflupane

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : PPD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety, Biodistribution, Internal Radiation Dosimetry, and Effective Dose of DaTSCANâ...

                            Details : Ioflupane is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            September 25, 2020

                            Lead Product(s) : Ioflupane

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : PPD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            GE Healthcare

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            GE Healthcare

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ioflupane

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : PPD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Diagnostic Efficacy of DaTSCANâ„¢ Ioflupane (123I) Injection in Single Photon Emis...

                            Details : Ioflupane is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Parkinsonian Disorders.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            December 10, 2019

                            Lead Product(s) : Ioflupane

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : PPD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth